Cellules souches

Type de données probantes

Étude randomisée chez l’humain

Direct UC-MSC randomized knee-osteoarthritis evidence

Publication et résultat principal

Intra-articular injection of umbilical cord-derived mesenchymal stem cells is safe and effective for moderate to severe knee osteoarthritis with synovitis: a double‑blinded and randomized controlled trial.

In a 55-participant double-blind randomized trial, UC-MSC injection produced significant six-month improvements in pain, function and synovitis among participants with knee osteoarthritis and synovitis; no serious treatment-related adverse events were reported.

BMC musculoskeletal disorders

Source

PMID 41466394 · 2025

Type de données probantes

Étude randomisée chez l’humain

Direct UC-MSC randomized aging-frailty evidence

Publication et résultat principal

Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study.

A randomized, double-blind, placebo-controlled frailty study reported six-month improvements in physical quality-of-life scores, timed up-and-go and grip strength, with no difference in adverse-event incidence between groups.

Stem cell research & therapy

Source

PMID 38679727 · 2024

Type de données probantes

Étude randomisée chez l’humain

Direct UC-MSC randomized phase II type-2-diabetes evidence

Publication et résultat principal

Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial.

In a 91-person double-blind phase II trial, 20% of the UC-MSC group versus 4.55% of the placebo group met the combined 48-week HbA1c and insulin-reduction endpoint; no major transplantation-related adverse events were reported.

Stem cell research & therapy

Source

PMID 35505375 · 2022

Type de données probantes

Étude randomisée chez l’humain

Direct UC-MSC randomized phase I/II heart-failure evidence

Publication et résultat principal

Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]).

In a 30-person phase I/II randomized heart-failure trial, the UC-MSC group showed improvements in left-ventricular ejection fraction, functional class and quality of life, with no infusion-related adverse events reported.

Circulation research

Source

PMID 28974553 · 2017